Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00126815
First received: August 3, 2005
Last updated: December 8, 2011
Last verified: December 2011
  Purpose

Clinical data are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.


Condition
Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 1000
Study Start Date: February 2004
Study Completion Date: April 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Clinical data (prostate-specific antigen [PSA] response after radiotherapy) are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • Prostate cancer treated with radiotherapy +/- hormones

Exclusion Criteria:

  • Prostatectomy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00126815

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Matthew Parliament, MD AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00126815     History of Changes
Other Study ID Numbers: NA-15-0002
Study First Received: August 3, 2005
Last Updated: December 8, 2011
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
prostate cancer
prostate specific antigen
radiotherapy
mathematical modeling

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on April 20, 2014